Table 2.
Comparison between the number of diagnoses of each type of head and neck cancer in the last 5 years and in the pandemic period of COVID-19 (March 1, 2020—November 1, 2020)
| Type of tumor | March 12—November 1, 2020 | March 12—November 1, 2019 | March 12—November 1, 2018 | March 12—November 1 2017 | March 12—November 1 2016 | March 12—November 1, 2015 |
|---|---|---|---|---|---|---|
| Laryngeal cancer | 16 (34%) | 21 (28.4%) | 26 (30.9%) | 14 (18.6%) | 37 (46.2%) | 22 (27.8%) |
| Laryngeal dysplasia | 7 (14.9%) | 8 (10.8%) | 13 (15.5%) | 11 (14.7%) | 4 (5%) | 12 (15.2%) |
| Laryngeal in situ cancer | 1 (2.1%) | 4 (5.4%) | 8 (9.5%) | 7 (9.3%) | 11 (13.7%) | 13 (16.4%) |
| Parotid cancer | 4 (8.5%) | 9 (12.1%) | 7 (8.3%) | 13 (17.3%) | 5 (6.2%) | 5 (6.3%) |
| Nasopharynx cancer | 4 (8.5%) | 5 (6.7%) | 4 (4.7%) | 2 (2.7%) | 5 (6.2%) | 3 (3.8%) |
| Submandibular gland cancer | 1 (2%) | 3 (4%) | 2 (2.3%) | 2 (2.7%) | 0 | 2 (2.5%) |
| Laterocervical metastases | 3 (6.4%) | 0 | 6 (7.1%) | 6 (8%) | 2 (2.5%) | 4 (5%) |
| Tongue cancer | 0 | 2 (2.7%) | 2 (2.3%) | 6 (8%) | 5 (6.2%) | 3 (3.8%) |
| Nasal cancer | 5 (10.6%) | 7 (9.4%) | 10 (11.9%) | 7 (9.3%) | 4 (5%) | 3 (3.8%) |
| Ear cancer | 0 | 5 (6.7%) | 1 (1.2%) | 2 (2.7%) | 1 (1.2%) | 3 (3.8%) |
| Oral cancer | 6 (12.7%) | 10 (13.5%) | 5 (5.9%) | 5 (6.7%) | 6 (7.5%) | 9 (11.4%) |